Podcast 48: A conversation with Les Irwig, which your bone scanner won’t like to hear.

Scanning patients on bisphosphonates within the first 3 years of therapy is just wasted effort, and may even be misleading clinically. That’s what researchers conclude after reanalysis of FIT trial data on some 6500 women taking either alendronate or placebo. Prof. Les Irwig of the University of Sydney talks about his team’s findings and what they mean for clinicians used to doing densitometric studies to reassure patients about the progress of their therapy.

This week’s news links:

• Diabetic Retinopathy, But Not Nephropathy, Benefits from Renin-Angiotensin Blockade
• FDA Panel Votes to Ban Vicodin, Percocet
• Value of CRP and Other Cardiovascular-Risk Biomarkers Questioned
• Insulin Glargine Associated with Cancer Risk; ADA Calls Findings “Conflicting and Confusing”

This week’s Interview links:

• Bone-Density Monitoring After Starting Bisphosphonates ‘Cannot Be Justified’
• BMJ article

The post Podcast 48: A conversation with Les Irwig, which your bone scanner won’t like to hear. first appeared on Clinical Conversations.